Antibody 8F5 targeting CEACAM6 was designed in lung adenocarcinoma to recognize the B domain of CEACAM6 [48], reduce the expression of CEACAM6 in cells, and thus significantly improve the anoikis sensitivity of cells through activation of caspase. The gene discussed is CEACAM6; the disease is lung adenocarcinoma.